Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BIO-TECHNE CORPORATION

(TECH)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/07/2021 06/08/2021 06/09/2021 06/10/2021 06/11/2021 Date
419.73(c) 425.03(c) 429.16(c) 435.8(c) 443.94(c) Last
215 634 132 661 196 256 198 015 174 306 Volume
-1.08% +1.26% +0.97% +1.55% +1.87% Change
More quotes
Financials (USD)
Sales 2021 924 M - -
Net income 2021 167 M - -
Net Debt 2021 10,0 M - -
P/E ratio 2021 107x
Yield 2021 0,29%
Sales 2022 1 054 M - -
Net income 2022 210 M - -
Net cash position 2022 348 M - -
P/E ratio 2022 86,1x
Yield 2022 0,29%
Capitalization 17 266 M 17 266 M -
EV / Sales 2021 18,7x
EV / Sales 2022 16,0x
Nbr of Employees 2 300
Free-Float 99,4%
More Financials
Company
Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through two segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences reporting segment supplies specialized proteins, such as cytokines and growth factors, immunoassays, antibodies and reagents, to the biotechnology community. The... 
More about the company
Ratings of Bio-Techne Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about BIO-TECHNE CORPORATION
06/11INSIDER TRENDS : 90-Days of Insider Buying at Bio-Techne Slowed with Share Sale
MT
06/10BIO TECHNEá : Further Enhances Its Gene Engineering & Cell & Gene Therapy Manufa..
PR
06/09BIO TECHNEá : Corporate Presentation – June 2021
PU
06/08BIO TECHNEá : Joins Cell and Gene Therapy Catapult Process Analytical Technology..
PR
06/02RENALYTIX AIá : JV Kantaro Biosciences Awarded Health Canada Authorization for C..
MT
06/02BIO TECHNEá : Kantaro's Semi-Quantitative Antibody Test Kit Receives Health Cana..
PR
05/27INSIDER TRENDS : Insider Sale Eases Back 90-Day Buy Trend at Bio-Techne
MT
05/27INSIDER TRENDS : Bio-Techne Insider Converts Option/Derivative Security Sells Po..
MT
05/19BIO TECHNEá : To Present At The Jefferies Virtual Healthcare Conference
PR
05/18BIO TECHNEá : to Collaborate With Narayana Nethralaya to Develop Diagnostics for..
MT
05/18BIO TECHNEá : and Narayana Nethralaya Collaborate on the use of Ella for Ophthal..
PR
05/14BIO-TECHNE CORPORATION : Ex-dividend day for
FA
05/10BIO TECHNEá : Multisite Study Demonstrates Utility of Asuragen Kit for Identifyi..
PR
05/07BIO TECHNEá : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL (form 10-Q)
AQ
05/07BIO TECHNEá : Baird Adjusts Price Target on Bio-Techne to $430 From $410, Keeps ..
MT
More news
News in other languages on BIO-TECHNE CORPORATION

- No features available -

More news
Analyst Recommendations on BIO-TECHNE CORPORATION
More recommendations
Chart BIO-TECHNE CORPORATION
Duration : Period :
Bio-Techne Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIO-TECHNE CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 430,00 $
Last Close Price 443,94 $
Spread / Highest target 12,6%
Spread / Average Target -3,14%
Spread / Lowest Target -51,6%
EPS Revisions
Managers and Directors
NameTitle
Charles R. Kummeth President, Chief Executive Officer & Director
James T. Hippel CFO & Principal Accounting Officer
Robert V. Baumgartner Chairman
Robert Monroe Chief Medical Officer
Brenda Swierenga Furlow Secretary, Senior Vice President & General Counsel
Sector and Competitors
1st jan.Capitalization (M$)
BIO-TECHNE CORPORATION39.80%17 266
MODERNA, INC.109.49%87 874
LONZA GROUP AG16.32%54 656
IQVIA HOLDINGS INC.35.87%46 658
CELLTRION, INC.-26.04%32 458
SEAGEN INC.-10.60%28 416